C4 Therapeutics Initiates Stock Option Repricing for Retention
Company Announcements

C4 Therapeutics Initiates Stock Option Repricing for Retention

C4 Therapeutics (CCCC) has shared an update.

C4 Therapeutics, Inc. has initiated a strategic repricing of stock options to incentivize and retain key employees. The repricing impacts certain underwater stock options under the 2020 Plan, adjusting the exercise price to align with past IPO and high trading values. Senior leadership team members’ options are now priced at $19.00 per share, while others are set at $11.88. This move, designed to motivate without diluting stock or increasing cash outlay, comes with a stipulation that any termination or exercise within a year returns the exercise price to its original amount, preserving the company’s financial interests.

Learn more about CCCC stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskC4 Therapeutics Advances in Protein Degradation Therapy
TheFlyC4 Therapeutics files $400M mixed securities shelf
TheFlyC4 Therapeutics files to sell 4.87M shares of common stock for holders
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App